The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2).sub.n-].sub.mP-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.

Provided is a new boron isotope (.sup.10B) tracing drug which can exhibit wide-area molecular-targeting function and stereotactic destructive power. The invented boron isotope (.sup.10B) tracing drug has higher selective tumor-targeting and tumor-accumulating pharmacokinetic functions appropriate for neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT).

The present invention is the creation of stable boron isotope (.sup.10B) containing nanosilica particles composing of amino acids, amino-oligosaccharides, and oligopeptides appropriate to the improvement of drug delivery system (DDS) function of delivering more boron to tumors selectively to facilitate the efficacy of boron neutron capture therapy (BNCT).

To provide a novel boron-containing compound. A compound represented by the following formula: wherein black circle represents B, white circles represent B—H; —R.sup.1 represents —(CH.sub.2)n-X.sup.1—R.sup.3 (n represents an integer of 0 to 6; X.sup.1 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; R.sup.3 represents C.sub.6-C.sub.20 alkyl, hydroxy C.sub.6-C.sub.20 alkyl, amino C.sub.6-C.sub.20 alkyl, azido C.sub.6-C.sub.20 alkyl, hydroxycarbonyl C.sub.6-C.sub.20 alkyl, or the like), or a group having a repeating sequence of —(CH.sub.2).sub.2—O— 3 times or more and 10 times or less and having a methyl group or an ethyl group at the end on the oxygen atom side; and —R.sup.2 is —(CH.sub.2)m-X.sup.2—R.sup.4 (m represents an integer from 0 to 8; X.sup.2 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; and R.sup.4 represents a tumor recognition moiety), or does not exist are prepared and used. ##STR00001##

A measurement device includes a sensing portion and a measuring portion. The sensing portion contains at least a fluorescent material whose emitting of fluorescent light ceases due to an action of a radioactive beam. The measuring portion measures a radiation quantity of the radioactive beam, with which the sensing portion is irradiated, based on an amount of decrease in the intensity of the fluorescent light emitted by the fluorescent material contained in the sensing portion when the radioactive beam acts on at least a portion of the fluorescent material. The fluorescent light is emitted due to irradiation of the fluorescent material by an excitation source.

The purpose of the present invention is to provide a .sup.10B medicine that can be selectively accumulated in tumor tissues at a low dose in a short time, and can be applied to BNCT. The .sup.10B medicine comprises a compound containing: a peptide capable of selectively binding to tumor vascular endothelial cells; and .sup.10B, wherein the .sup.10B medicine is administered to a subject suffering from cancer at a dose of 300-600 mg per administration, and is accumulated after the administration such that the concentration of .sup.10B in the cancer tissue of the subject becomes 1 ppm or higher.

The invention provides a nanovehicle, comprising: a core, wherein the core comprises at least one iron oxide: a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one boron cluster. The invention provides a method of treating a disease, disorder, or disease condition in a subject, comprising administering a therapeutically effective amount of the nanovehicle to the subject; and radiating the nanovehicle with neutrons. In various embodiments, the invention provides a method for detecting a cancer in a subject, comprising administering an effective amount of at least one nanoparticle of the present invention to the subject. The invention also provides the nanovehicles (e.g., nanoparticles) described herein in the form of various pharmaceutical formulations. The invention provides a kit, the kit comprises: a quantity of the nanovehicle (e.g., nanoparticle) described herein.

The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.

Provided are a boric acid-containing polyvinyl alcohol nanoparticle and a preparation method thereof. The boric acid-containing polyvinyl alcohol nanoparticle includes a polyvinyl alcohol nanoparticle and a boric acid, wherein the boric acid is crosslinked to the polyvinyl alcohol nanoparticle by covalent bonds.